However, by mid-2020, UCB reported that in a phase 2b study in drug-resistant focal epilepsy patients, padsevonil did not reach statistical significance for either of the primary endpoints; thus, its development program was terminated despite its good pharmacological and safety profiles [ 98 ].
1
—
—